Last reviewed 2026-04-22 · How we verify

NicodermCQ

NicodermCQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation.

NicodermCQ delivers nicotine transdermally to replace nicotine from cigarettes and reduce withdrawal symptoms during smoking cessation. Used for Smoking cessation as an aid to quit smoking.

At a glance

Mechanism of action

The patch provides a steady, controlled release of nicotine through the skin into the bloodstream, bypassing the need for smoking. This maintains nicotine levels to suppress cravings and withdrawal symptoms (irritability, anxiety, difficulty concentrating) while the user gradually reduces dependence. The transdermal route avoids the harmful combustion products of cigarettes while allowing behavioral modification.

Approved indications

• Smoking cessation as an aid to quit smoking

Common side effects

• Skin irritation at patch site
• Headache
• Nausea
• Dizziness
• Sleep disturbances
• Vivid dreams

Key clinical trials

• Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation (PHASE4)
• Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers (PHASE4)
• Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• NicodermCQ CI brief — competitive landscape report
• NicodermCQ updates RSS · CI watch RSS
• University of Chicago portfolio CI